Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osivelotor - Global Blood Therapeutics/Pfizer

Next Previous
X
Search
Drug Profile

Osivelotor - Global Blood Therapeutics/Pfizer

Alternative Names: GBT-021601; GBT-601; PF-07940367

Latest Information Update: 04 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Global Blood Therapeutics; Pfizer
  • Class Antianaemics; Small molecules; Urologics
  • Mechanism of Action Sickle haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase I Renal failure

Most Recent Events

  • 19 Sep 2024 Pfizer terminates a phase-I trial in Renal failure in USA (PO) due to business decision (NCT05878704)
  • 31 Jul 2024 Phase-III clinical trials in Sickle cell anaemia in USA (PO) before July 2024 (Pfizer pipeline, July 2024)
  • 31 Jul 2024 Osivelotor - Global Blood Therapeutics/Pfizer receives Fast Track designation for Sickle cell anaemia [PO] in USA before July 2024 (Pfizer pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top